Gemcitabine, paclitaxel, and piritrexim: A phase I study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 3, 2003, Pages 280-284

  Liu, Glenn ^b   Bailey, Howard H ^b   Arzoomanian, Rhoda Z ^b   Alberti, Dona ^b   Binger, Kimberly ^b   Volkman, Jennifer ^b   Feierabend, Chris ^b   Marnocha, Rebecca ^b   Wilding, George ^b   Thomas, James P ^a  

^a Medical Oncology Section   (United States)

^b NONE

Author keywords

Antifolates; Gemcitabine; Paclitaxel; Phase I; Piritrexim

Indexed keywords

ANTINEOPLASTIC AGENT; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID ANTAGONIST; GEMCITABINE; PACLITAXEL; PIRITREXIM;

ADULT; AGED; ANOREXIA; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DISEASE COURSE; DYSPNEA; EDEMA; FEMALE; HICCUP; HUMAN; INFECTION; LEUKOCYTE COUNT; LIVER TOXICITY; LUNG CANCER; MALE; MYALGIA; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; RASH; SARCOMA; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERUS CANCER; VOMITING;

EID: 0037841388     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000081607.16287.6f     Document Type: Article

References (30)

1. Galivan J. Transport and mechanism of methotrexate in normal and resistant cultured rat hepatoma cells. Cancer Res 1979;39: 735-43.
2. Sirotnak FM. Determinants of resistance to antifolates: biochemical phenotypes, their frequency of occurrence and circumvention. NCl Monogr 1987;5:27-35.
3. Sigel CW, Macklin AW, Wooley JL, et al. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophile inhibitor of dihydrofolate reductase. NCl Monogr 1987;5:111-20.
4. Duch DS, Edelstein MP, Bowers SW, et al. Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyridol[2,3-d]pyrimidine (BW301U), a novel lipid-soluble inhibitor of dihydrofolate reductase. Cancer Res 1982;42: 3987-94.
5. Taylor IW, Slowizczek P, Friedlander ML, et al. Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake. Cancer Res 1985;45:978-82.
6. Marshall M, Von Hoff D, Chacko A. Effects of drug concentration, exposure time, and serum dialysis on antitumor activity of BW301U in the human tumor cloning assay. Taken from: Proc Am Assoc Cancer Res 1985;26:364.
7. Laszlo J, Brenckman WD, Morgan E, et al. Initial clinical studies of piritrexim. NCl Monogr 1987;5:121-5.
8. De Wit R, Kaye SB, Roberts JT, et al. Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 1993;67: 388-90.
9. Feun LG, Savaraj N, Benedetto P, et al. Oral piritrexim in advanced bladder cancer: an effective drug after progression on MVAC chemotherapy. Am J Clin Oncol 1994;17:448-51.
10. Uen WC, Huang AT, Mennel R, et al. A phase II study of piritrexim in patients with advanced head and neck cancer. Cancer 1992;69:1008-11.
11. Schiesel JD, Carabasi M, Magill G, et al. Oral piritrexim - a phase II study in patients with advanced soft tissue sarcoma. Invest New Drugs 1992;10:97-8.
12. Feun LG, Gonzales R, Savaraj N, et al. Phase II trial of piritrexim in metastatic melanoma using an intermittent, low dose administration. J Clin Oncol 1991;9:464-7.
13. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-70.
14. Pollera CF, Ceribelli A, Crecco M, et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report. Ann Oncol 1994; 5:182-4.
15. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:2294-8.
16. Shepard FA. Phase II trials of single-agent gemcitabine in patients with advanced non-small cell lung cancer: an overview. Anticancer Drugs 1995;6:19-25.
17. Roberts D, Hall TC, Rosenthal D. Coordinated changes in biochemical patterns: the effect of cytosine arabinoside and methotrexate on leukocytes from patients with acute granulocytic leukemia. Cancer Res 1969;29:571-8.
18. Russel DH. Effects of methotrexate and cytosine arabinoside on polyamine metabolism in a mouse L1210 leukemia. Cancer Res 1972;32:2459-62.
19. Roberts D, Peck C. Effect of methotrexate and 1-β-D-arabinofuranosylcytosine on pools of deoxyribonucleoside triphosphates in L1210 cells. Cancer Res 1981;41:501-10.
20. Jackson RC, Harkrader RJ. Synergistic and antagonistic interactions of methotrexate and 1-β-D-arabinofuranosylcytosine in hepatoma cells. Biochem Pharmacol 1980;30:223-9.
21. Newman EM, Villacorte DG, Testi AM, et al. Biochemical interactions between methotrexate and 1-β-D-arabinofuranosylcytosine in hematopoietic cells of children. Cancer Chemother Pharmacol 1990;27:60-6.
22. Adejei AA. Gemcitabine and pemetrexed disodium in treating breast cancer. Oncology 2001;15(suppl 3):34-7.
23. Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000;18:1748-57.
24. Adjei AA, Erlichman C. A phase I trial of MTA and gemcitabine in patients with locally advanced metastatic cancer. Semin Oncol 1999;26(suppl 6):94-8.
25. Tonkinson JL, Worzalla JF, Teng CH, et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999;59:3571-76.
26. Adjei AA. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 2000;11:1335-41.
27. Rothenberg ML, Sharma A, Weiss GR, et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory tumors. Ann Oncol 1998;9:733-8.
28. De Pas T, de Braud F, Danesi R, et al. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small cell lung cancer. Ann Oncol 2000; 11:821-7.
29. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001;19:3018-24.
30. Feun LG, Savaraj N, Benedetto P, et al. Phase I trial of piritrexim capsules using prolonged low-dose oral administration for the treatment of advanced malignancies. J Natl Cancer Inst 1991; 83:51-5.